İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2024

Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort

UROLOGY JOURNAL

YÖKSİS OpenAlex Açık erişim · green SJR Q3 JCR Q4 Atıf 0 Yüzdelik 13.3% FWCI 0.0
Yıl
2024
ISSN
1735-546X
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

PURPOSE: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications. MATERIALS AND METHODS: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype. RESULTS: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM. CONCLUSION: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.

Konular

  • Renal cell carcinoma treatment
  • Bladder and Urothelial Cancer Treatments
  • Multiple and Secondary Primary Cancers

Birincil konu Renal cell carcinoma treatment

Yazarlar

  1. HAKAN TAHA ÇETİN
  2. SERDAR ÇELİK
  3. TEVFİK SİNAN SÖZEN
  4. EVREN SÜER ANKARA ÜNİVERSİTESİ
  5. VOLKAN İZOL
  6. TALHA MÜEZZİNOĞLU MANİSA CELÂL BAYAR ÜNİVERSİTESİ